Allurion Technologies Inc
Company Profile
Business description
Allurion Technologies Inc is a medical device company that focuses on creating a weight loss platform to treat overweight patients. Its platform, the Allurion Program, features the world’s first and only swallowable, procedure-less intragastric balloon for weight loss and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion VCS. Its proprietary intragastric balloon, the Allurion Balloon, is in the form of a swallowed capsule that is administered to patients under the guidance of a healthcare provider without surgery, endoscopy, or anesthesia.
Contact
11 Huron Drive
NatickMA01760
USAT: +1 508 647-4000
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2026
Employees
137
Stocks News & Analysis
stocks
Undervalued ASX share with pathway to positive cash flow
stocks
Taiwan Semiconductor earnings: Buoyant guidance backed by voracious AI demand
stocks
Ahead of earnings, is Netflix a buy, a sell, or fairly valued?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,226.70 | 45.90 | 0.50% |
| CAC 40 | 8,236.23 | 76.89 | -0.92% |
| DAX 40 | 25,260.09 | 92.30 | -0.36% |
| Dow JONES (US) | 49,451.69 | 9.25 | 0.02% |
| FTSE 100 | 10,227.44 | 11.50 | -0.11% |
| HKSE | 26,844.96 | 78.66 | -0.29% |
| NASDAQ | 23,646.26 | 116.24 | 0.49% |
| Nikkei 225 | 53,936.17 | 174.33 | -0.32% |
| NZX 50 Index | 13,718.10 | 58.31 | 0.43% |
| S&P 500 | 6,961.26 | 16.79 | 0.24% |
| S&P/ASX 200 | 8,903.90 | 48.10 | 0.54% |
| SSE Composite Index | 4,101.91 | 10.69 | -0.26% |